TY - JOUR
T1 - Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol
AU - Morabito, Fortunato
AU - Tripepi, Giovanni
AU - Vigna, Ernesto
AU - Bossio, Sabrina
AU - D’Arrigo, Graziella
AU - Martino, Enrica Antonia
AU - Storino, Francesca
AU - Recchia, Anna Grazia
AU - Fronza, Gilberto
AU - Di Raimondo, Francesco
AU - Colombo, Monica
AU - Fais, Franco
AU - Neri, Antonino
AU - Cutrona, Giovanna
AU - Ferrarini, Manlio
AU - Gentile, Massimo
N1 - Funding Information:
Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 x 1000 n.9980 (to FM, MF, AN); AIRC and Fondazione CaRiCal co‐financed Multi‐Unit Regional Grant 2014 n.16695 to FM; AIRC, Special Program Metastases (n. 21198) 5x1000 to R.F; AIRC IG‐5506 to GF, IG‐14326 (to MF), IG‐15426 (to FF); Compagnia S. Paolo, Turin, Italy, Project 2017.0526 (to GF) and by the Ministry of Health (Project 5x1000, 2015 and 2016 and Current Research 2016 (to GF, GC, and FF).
Publisher Copyright:
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2021
Y1 - 2021
N2 - Objectives: To validate the predictive value on time to first treatment (TTFT) of AIPS-E and IPS-E evaluated in an independent cohort of newly diagnosed and non-referred Binet stage A CLL patients enrolled in the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540). Methods: A cohort of 292 newly diagnosed Binet A CLL cases has been enrolled in the study. Patients from several Italian Institutions were prospectively enrolled within 12 months of diagnosis into the O-CLL1-GISL protocol. Results: The majority of patients were male (62%); median age was 60.4 years, 102 cases (34.9%) showed unmutated IGHV genes, 8 cases (2.8) the presence of del(11q)/del(17p), 142 cases (48.6%) the presence of palpable lymph nodes and 146 cases (50%) and ALC > 15 × 109/l. After a median follow-up of 7.2 years, 130 patients underwent treatment. According to the AIPS-E, 96 patients were classified as low-risk, 128 as intermediate-risk, and 68 as high-risk. These groups showed significant differences in terms of TTFT. The C-statistic was 0.71 (P <.0001) for predicting TTFT. According to IPS-E, 77 patients were classified as low-risk, 135 as intermediate-risk, and 80 as high-risk. These groups showed significant differences in terms of TTFT. The C-statistic was 0.705 (P <.0001) for predicting TTFT. Conclusions: Our data confirm an accurate prognostic utility of both AIPS-E and IPS-E at the individual patient level. These data may be useful for a precise stratification of early-stage patients.
AB - Objectives: To validate the predictive value on time to first treatment (TTFT) of AIPS-E and IPS-E evaluated in an independent cohort of newly diagnosed and non-referred Binet stage A CLL patients enrolled in the O-CLL1-GISL protocol (clinicaltrial.gov identifier: NCT00917540). Methods: A cohort of 292 newly diagnosed Binet A CLL cases has been enrolled in the study. Patients from several Italian Institutions were prospectively enrolled within 12 months of diagnosis into the O-CLL1-GISL protocol. Results: The majority of patients were male (62%); median age was 60.4 years, 102 cases (34.9%) showed unmutated IGHV genes, 8 cases (2.8) the presence of del(11q)/del(17p), 142 cases (48.6%) the presence of palpable lymph nodes and 146 cases (50%) and ALC > 15 × 109/l. After a median follow-up of 7.2 years, 130 patients underwent treatment. According to the AIPS-E, 96 patients were classified as low-risk, 128 as intermediate-risk, and 68 as high-risk. These groups showed significant differences in terms of TTFT. The C-statistic was 0.71 (P <.0001) for predicting TTFT. According to IPS-E, 77 patients were classified as low-risk, 135 as intermediate-risk, and 80 as high-risk. These groups showed significant differences in terms of TTFT. The C-statistic was 0.705 (P <.0001) for predicting TTFT. Conclusions: Our data confirm an accurate prognostic utility of both AIPS-E and IPS-E at the individual patient level. These data may be useful for a precise stratification of early-stage patients.
KW - AIPS-E
KW - CLL
KW - early stage
KW - prognosis
KW - TTFT
UR - http://www.scopus.com/inward/record.url?scp=85103638537&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103638537&partnerID=8YFLogxK
U2 - 10.1111/ejh.13614
DO - 10.1111/ejh.13614
M3 - Article
C2 - 33662164
AN - SCOPUS:85103638537
VL - 106
SP - 831
EP - 835
JO - European Journal of Haematology
JF - European Journal of Haematology
SN - 0902-4441
IS - 6
ER -